We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01380769
Recruitment Status : Completed
First Posted : June 27, 2011
Results First Posted : May 24, 2017
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
Lumos Pharma ( NewLink Genetics Corporation )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to compare median overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with CRLX101 to patients treated with best supportive care (BSC).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: CRLX101 Other: Best Supportive Care Phase 2

Detailed Description:
Lung cancer remains the leading cause of cancer-related mortality in men and women worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer. The development of targeted therapies has changed the approach to treating NSCLC significantly over the past decade with targeted therapies generally possessing safety advantages over traditional cytotoxic regimens. However, combination paradigms and resistance patterns complicate the use of these agents. CRLX101 is a nanoparticle comprised of camptothecin (CPT) conjugated to a cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 157 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy
Study Start Date : June 2011
Actual Primary Completion Date : February 2013
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CRLX101 Drug: CRLX101
CRLX101 is administered at 15mg/m2 IV every other week
Other Name: NLG207
Best supportive care Other: Best Supportive Care
best supportive care


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only [ Time Frame: Up to 18 months ]
    Comparison of survival among patients treated with CRLX101 + best supportive care vs patients treated wiht best supportive care only.


Secondary Outcome Measures :
  1. Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only [ Time Frame: 12 months ]
    Comparison of objective response rate in subjects treated with CRLX101+BSC versus subjects treated with BSC alone.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients who are ≥ 18-years of age.
  • Histologically or cytologically confirmed, locally advanced or metastatic NSCLC (adenocarcinoma, bronchoalveolar, squamous cell, large cell, or mixed carcinoma) that is not amendable to surgical treatment and patient has have failed 1 or 2 different lines of chemotherapy.
  • Measureable disease and evidence of progression on the previous therapy. Progression may be clinical or radiological.
  • ECOG performance status of 0 or 1.
  • Life expectancy of at least 3 months.
  • Hemoglobin ≥ 10 g/dL.
  • Absolute neutrophil count (ANC) ≥ 1500 cells/µL without growth factor support.
  • Platelet count ≥ 100,000 cells/µL without support.
  • Adequate hepatic and renal function including the following: Total bilirubin < 2 × ULN, AST or ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastasis, PTT within normal limits, INR ≤ 1.5, Serum Creatinine <1.5 ULN
  • At least 4 weeks post any radiotherapy or biological therapy; at least 6 weeks post nitrosoureas therapy.
  • Full recovery from diagnostic or therapeutic surgery (i.e., complete wound healing) and at least 30 days have elapsed prior to initial dosing.
  • Full recovery from the toxic effects of prior therapy (i.e., Common Toxicity Criteria [CTC] Grade 1 or less with the exception of Grade 2 alopecia).
  • Women of childbearing potential must have adequate pregnancy test. If postmenopausal, must be ≥ 12 months since last menses.
  • Women of childbearing potential and men must agree to use an effective form of contraception during the study and for 60 days after the last dose of study drug.

Exclusion Criteria:

  • CNS metastases by radiologic evidence or histology, unless clinically stable (must have been treated by resection or radiation) for at least 4 weeks prior to first dose of study drug. Patients may not be receiving dexamethasone for control of CSF pressure.
  • Concurrent therapeutic anticoagulation: PTT less than or equal to 1.5 × ULN or low dose aspirin and low-weight heparin only are allowed.
  • More than 2 previous lines of chemotherapy for lung cancer. This includes biologic (immunotherapy) therapy.
  • History of previous cerebrovascular accident (CVA) or history transient ischemic attack (TIA) within 6 months of study entry.
  • History of prior malignancy not cured by excision. Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not excluded, but patients with other prior malignancies must have had at least 2-year disease free interval.
  • Recent history (within 6 months of screening) of unstable angina, myocardial infarction, or NYHA Class III or IV congestive heart failure
  • History of cardiac arrhythmia requiring medical or electrical therapy.
  • QTc > 450 msec for males and > 470 msec for females.
  • Any major surgery within 30 days or minor surgery within 10 days of study entry, or patient not recovered from surgery.
  • History of organ or bone marrow transplant.
  • Known active and/or uncontrolled infection, including HIV and are not stable on antiretroviral therapy.
  • Any investigational therapy within 28 days of study entry.
  • Pregnant or nursing.
  • Anyone who in the judgment of the investigator cannot comply with the protocol, provide truly informed consent, or is likely to live < 90 days
  • Severe or significant allergy to any chemotherapy or premedication.
  • Clinically evident ascites (e.g., abdominal distention, bulging and/or fluid wave) or Grade 3 peripheral edema.
  • Any prior cancer treatment with a topoisomerase I inhibitor.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380769


Locations
Show Show 25 study locations
Sponsors and Collaborators
NewLink Genetics Corporation
Investigators
Layout table for investigator information
Study Chair: NewLink Genetics NewLink Genetics Inc
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: NewLink Genetics Corporation
ClinicalTrials.gov Identifier: NCT01380769    
Other Study ID Numbers: CRLX-002
First Posted: June 27, 2011    Key Record Dates
Results First Posted: May 24, 2017
Last Update Posted: May 28, 2020
Last Verified: May 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms